​

vTv Therapeutics (VTVT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

VTVT Stock Forecast

vTv Therapeutics (VTVT) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $51.33, with a high of $58.00 and a low of $47.00. This represents a 46.24% increase from the last price of $35.10.

$10 $20 $30 $40 $50 $60 High: $58 Avg: $51.33 Low: $47 Last Closed Price: $35.1

VTVT Stock Rating

vTv Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (50.00%), 7 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 7 7 Strong Sell Sell Hold Buy Strong Buy

VTVT Price Target Upside V Benchmarks

TypeNameUpside
StockvTv Therapeutics46.24%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-33
Avg Price Target-$51.33$51.33
Last Closing Price$35.10$35.10$35.10
Upside/Downside-46.24%46.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-5---5
Feb, 26-5---5
Jan, 26-21--3
Dec, 25-21--3
Nov, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026Kambiz YazdiBTIG$49.00$33.8644.71%39.60%
Jan 22, 2026Roth Capital$58.00$33.5472.93%65.24%
Dec 19, 2025H.C. Wainwright$47.00$36.3029.48%33.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2026Evercore ISIOutperforminitialise
Mar 11, 2026BTIGBuyBuyhold
Jan 27, 2026BTIGBuyBuyhold
Jan 22, 2026Roth CapitalBuyinitialise
Jan 05, 2026Cowen & Co.Buyinitialise
Dec 19, 2025H.C. WainwrightBuyBuyhold
Feb 18, 2022Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-8.29$-9.98$-9.71$-3.20$-3.20--
Avg Forecast$-6.80$-10.80$-31.20$-3.65$-4.85$-5.10$-5.20
High Forecast$-6.80$-10.80$-31.20$-3.65$-4.85$-5.10$-5.20
Low Forecast$-6.80$-10.80$-31.20$-3.65$-4.85$-5.10$-5.20
Surprise %21.91%-7.59%-68.88%-12.33%-34.02%--

Revenue Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$4.00M$2.02M-$1.02M---
Avg Forecast$4.33M$2.01M-$1.00M---
High Forecast$4.33M$2.01M-$1.00M---
Low Forecast$4.33M$2.01M-$1.00M---
Surprise %-7.55%0.60%-1.70%---

Net Income Forecast

$-70M $-56M $-42M $-28M $-14M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-12.99M$-19.16M$-20.25M$-18.46M$-26.97M--
Avg Forecast$-14.18M$-6.38M$-65.05M$-7.61M$-10.11M$-10.63M$-10.84M
High Forecast$-14.18M$-4.19M$-65.05M$-7.61M$-10.11M$-10.63M$-10.84M
Low Forecast$-14.18M$-8.56M$-65.05M$-7.61M$-10.11M$-10.63M$-10.84M
Surprise %-8.40%200.60%-68.87%142.60%166.75%--

VTVT Forecast FAQ

Is vTv Therapeutics stock a buy?

vTv Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that vTv Therapeutics is a favorable investment for most analysts.

What is vTv Therapeutics's price target?

vTv Therapeutics's price target, set by 14 Wall Street analysts, averages $51.33 over the next 12 months. The price target range spans from $47 at the low end to $58 at the high end, suggesting a potential 46.24% change from the previous closing price of $35.1.

How does vTv Therapeutics stock forecast compare to its benchmarks?

vTv Therapeutics's stock forecast shows a 46.24% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for vTv Therapeutics over the past three months?

  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is vTv Therapeutics’s EPS forecast?

vTv Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.1, marking a 59.38% increase from the reported $-3.2 in 2025. Estimates for the following years are.

What is vTv Therapeutics’s revenue forecast?

vTv Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is vTv Therapeutics’s net income forecast?

vTv Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-10.633M, representing a -60.58% decrease from the reported $-26.974M in 2025. Projections indicate .